Isomorphic Labs Raises $2.1B for AI Drug Discovery
LONDON, May 12, 2026 Isomorphic Labs has secured a massive $2.1 billion Series B funding round to accelerate the...
Johnson & Johnson
Advertisement
Johnson & Johnson Showcases Neuropsychiatry Data at APA 2026
TITUSVILLE, N.J., May 11, 2026 Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the...
Johnson & Johnson Reports OTTAVA Surgical Robot Data
SANTA CLARA, Calif., United States – May 5, 2026 Johnson & Johnson has announced pivotal clinical study results for...
Johnson & Johnson Highlights CAPLYTA Superiority in MDD Study
TITUSVILLE, NEW JERSEY, May 04, 2026 Johnson & Johnson has announced new findings demonstrating that CAPLYTA® (lumateperone) achieved the...
Johnson & Johnson Strengthens CNS Portfolio with CAPLYTA FDA Nod
TITUSVILLE, NEW JERSEY, April 27, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for...
Advertisements
Johnson & Johnson PERSIGMA Trial Advances AFib Care
Irvine, California | April 24, 2026 Johnson & Johnson has announced the launch of the PERSIGMA randomized controlled trial...
Johnson & Johnson IMAAVY Delivers 2-Year gMG Control
HORSHAM, Pa., April 22, 2026 Johnson & Johnson has reported compelling long-term Phase 3 data demonstrating that IMAAVY® (nipocalimab-aahu)...
Johnson & Johnson IMAAVY Shows Strong Phase 3 gMG Data
Horsham, Pennsylvania, USA – April 22, 2026 In a major advancement for autoimmune neurology, Johnson & Johnson has reported...
Johnson & Johnson Launches VARIPULSE Pro in Europe
IRVINE, California, United States, April 7, 2026 Johnson & Johnson MedTech announced the European launch of VARIPULSE™ Pro, an...
Johnson & Johnson INLEXZO Gets J-Code for Cancer Access
RARITAN, N.J., USA — April 1, 2026 Johnson & Johnson announced that its innovative bladder cancer therapy INLEXZO™ (gemcitabine...
Advertisement
